(Q33330077)

25 July 2017

1 reference

title

Topotecan: a review of its efficacy in small cell lung cancer (English)

1 reference

25 July 2017

1 reference

D Ormrod

1

1 reference

25 July 2017

C M Spencer

series ordinal

2

1 reference

25 July 2017

publication date

1 September 1999

1 reference

25 July 2017

1 reference

25 July 2017

volume

58

1 reference

25 July 2017

issue

3

1 reference

25 July 2017

page(s)

533-551

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-199958030-00020

25 July 2017

exact match

0 references

cites work

Cancer statistics, 1998.

1 reference

12 December 2020

Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study

1 reference

12 December 2020

A new water-soluble camptothecin derivative, DX-8951f, exhibits potent antitumor activity against human tumors in vitro and in vivo.

1 reference

12 December 2020

Phase I and pharmacologic studies of topotecan in patients with impaired hepatic function

1 reference

12 December 2020

Cytotoxic activity of topotecan in human tumour cell lines and primary cultures of human tumour cells from patients

1 reference

12 December 2020

Synergistic cell killing by ionizing radiation and topoisomerase I inhibitor topotecan (SK&F 104864)

1 reference

12 December 2020

In vitro cross-resistance and collateral sensitivity in seven resistant small-cell lung cancer cell lines: preclinical identification of suitable drug partners to taxotere, taxol, topotecan and gemcitabin

1 reference

12 December 2020

Interaction of ionizing radiation with topotecan in two human tumor cell lines

1 reference

12 December 2020

In vitro and in vivo effects of clinically important camptothecin analogues on multidrug-resistant cells.

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks

1 reference

12 December 2020

Relation between age and clearance rate of nine investigational anticancer drugs from phase I pharmacokinetic data

1 reference

12 December 2020

Clinical pharmacokinetics of topotecan

1 reference

12 December 2020

Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I

1 reference

12 December 2020

Characterisation of a human small-cell lung cancer cell line resistant to the DNA topoisomerase I-directed drug topotecan

1 reference

12 December 2020

Plasma camptothecin (NSC-100880) levels during a 5-day course of treatment: relation to dose and toxicity.

1 reference

12 December 2020

Cyclophosphamide, doxorubicin, and vincristine in etoposide- and cisplatin-resistant small cell lung cancer.

1 reference

12 December 2020

Reduced cellular accumulation of topotecan: a novel mechanism of resistance in a human ovarian cancer cell line

1 reference

12 December 2020

Phase I and pharmacologic study of topotecan in patients with impaired renal function

1 reference

12 December 2020

Phase I study of paclitaxel and topotecan in patients with advanced tumors: a cancer and leukemia group B study

1 reference

12 December 2020

Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line

1 reference

12 December 2020

Small-cell lung cancer: treatment progress and prospects

1 reference

12 December 2020

A review of the pharmacology and clinical activity of new chemotherapeutic agents in lung cancer

1 reference

12 December 2020

Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan

1 reference

12 December 2020

Topoisomerase I inhibitors: topotecan and irenotecan

1 reference

12 December 2020

Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors

1 reference

12 December 2020

Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro

1 reference

12 December 2020

Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor

1 reference

12 December 2020

Life-threatening myelosuppression in patients with occult renal impairment receiving topotecan

1 reference

12 December 2020

New drugs for treating small cell lung cancer.

1 reference

12 December 2020

Topotecan. A review of its potential in advanced ovarian cancer

1 reference

12 December 2020

Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer

1 reference

12 December 2020

Cisplatin-topotecan-paclitaxel weekly administration with G-CSF support for ovarian and small-cell lung cancer patients: a dose-finding study.

1 reference

12 December 2020

Antiangiogenic effects of camptothecin analogues 9-amino-20(S)-camptothecin, topotecan, and CPT-11 studied in the mouse cornea model

1 reference

12 December 2020

Mechanisms of resistance in a human cell line exposed to sequential topoisomerase poisoning.

1 reference

12 December 2020

Topoisomerase I inhibitors: review and update

1 reference

12 December 2020

Five days of oral topotecan (Hycamtin), a phase I and pharmacological study in adult patients with solid tumours

1 reference

12 December 2020

Interpatient variability in bioavailability of the intravenous formulation of topotecan given orally to children with recurrent solid tumors

1 reference

12 December 2020

Pharmacokinetics and early clinical studies of selected new drugs.

1 reference

12 December 2020

Late recurrence of small-cell lung cancer: treatment and outcome

1 reference

12 December 2020

Comparative brain tissue distribution of camptothecin and topotecan in the rat.

1 reference

12 December 2020

A phase I and translational study of sequential administration of the topoisomerase I and II inhibitors topotecan and etoposide.

1 reference

12 December 2020

Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin

1 reference

12 December 2020

Topotecan in small cell lung cancer.

1 reference

12 December 2020

The pharmacokinetics of topotecan and its carboxylate form following separate intravenous administration to the dog.

1 reference

12 December 2020

A phase I study of topotecan followed sequentially by doxorubicin in patients with advanced malignancies.

1 reference

12 December 2020

Pediatric phase I trial and pharmacokinetic study of topotecan administered as a 24-hour continuous infusion

1 reference

12 December 2020

Phase I trial of paclitaxel, carboplatin, and topotecan with or without filgrastim (granulocyte-colony stimulating factor) in the treatment of patients with advanced, refractory cancer

1 reference

12 December 2020

Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue.

1 reference

12 December 2020

Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer

1 reference

12 December 2020

Topoisomerase inhibitors. A review of their therapeutic potential in cancer

1 reference

12 December 2020

Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer

1 reference

12 December 2020

Reporting results of cancer treatment

1 reference

12 December 2020

Phase II evaluation of topotecan for pediatric central nervous system tumors.

1 reference

12 December 2020

Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer.

1 reference

12 December 2020

Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial

1 reference

12 December 2020

A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin)

1 reference

12 December 2020

The significance of the sequence of administration of topotecan and etoposide

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer

1 reference

12 December 2020

Topotecan in combination chemotherapy.

1 reference

12 December 2020

Equilibrium kinetics of the new experimental anti-tumour compound SK&F 104864-A in aqueous solution

1 reference

12 December 2020

Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies.

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of topotecan given on a daily-times-five schedule in phase II clinical trials using a limited-sampling procedure

1 reference

12 December 2020

Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and

1 reference

12 December 2020

Prophylactic Cranial Irradiation for Patients With Small-Cell Lung Cancer in Complete Remission

1 reference

12 December 2020

A phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK&F 104864) given as an intravenous bolus every 21 days

1 reference

12 December 2020

10.2165/00003495-199958030-00020

Identifiers

DOI

1 reference

Dimensions Publication ID

25 July 2017

1008372655

0 references

1 reference